The role of the transvenous catheter electrophysiologic study in the evaluation and management of ventricular tachyarrhythmias associated with ischemic heart disease.
The transvenous-catheter electrophysiologic (EP) study has occupied a central position in the investigation and management of patients with ischemic heart disease and a propensity to ventricular tachycardia (VT) or ventricular fibrillation (VF) for more than 25 years. However, demonstration of the superiority of the implantable cardioverter defibrillator (ICD) compared to other approaches to the management of VT/VF has resulted in a decrease in the frequency of use of the EP study in these patients. Nevertheless, the EP study remains a value-added procedure for many patients in this setting. These advantages include demonstration that the clinical arrhythmia is VT/VF when the diagnosis is uncertain, identification of those patients whose VT/VF is actually the result of a supraventricular tachyarrhythmia, identification of VT mechanisms readily amenable to catheter ablation, assessment of the response of a patient's VT to attempts at pace-termination, evaluation of candidacy for ablative VT therapy, prediction of the efficacy of approaches to prevention of VT/VF episodes, risk stratification of patients who have not yet experienced a sustained episode of VT/VF, and continued enhancement of our understanding of the mechanisms and therapeutics of VT/VF. The purpose of this review is to outline our present understanding of the techniques and indications for an EP study in patients with ischemic heart disease.
Mitchell
L Brent
LB
Department of Cardiac Science, Calgary Health Region, Foothills Hospital, Calgary, Alberta, Canada. brent.mitchell@calgaryhealthregion.ca
D006328:Cardiac Catheterization / Q000379:methods; D017115:Catheter Ablation / Q000379:methods; D022062:Electrophysiologic Techniques, Cardiac / Q000379:methods*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D017180:Tachycardia, Ventricular / Q000150:complications / Q000175:diagnosis* / Q000601:surgery*; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000150:complications / Q000175:diagnosis / Q000601:surgery